This company invites all interested, both current investors and potential investors to participate in this event, ask questions directly on this page before the event starts and upvote those questions you would like addressed.
The company will address as many questions as possible, and focus on those questions most wanted by investors.
Avser ni låsa era aktier ytterligare ett år
Can you explain a bit the recent decrease in guidance, it is a significant decrease that requires some more information, for investors to understand?
Dont you think it would send a good message to the investors if you could show you still have good faith in the company with some insider buys, now you have dropped the q3 and the silence period is over and the stock took a huge hit and the wagering of the share on the market is very low because of the lack in confidence and people doesnt know what to think about the company at this moment? It would be nice to see if you can show us investors that you believe in the company with buys, and that is not just the sisters, other board members, family members, Heidi and Mikkel aswell.
Apparently, you have been unable to start production for lack of cash. I assume you set a budget at the start of Q1 with enough cash for the production you expected then (and that was before the RongShi agreement). So what have gone wrong? Some source of financing failed to materialize?
In the Q3 report, there is 4,2 million in trade receivables. Most of which seems to go back to Q4 of last year. How do you view the chances of this getting paid?
Can you explain why a small danish company with revenue of only 1 million is focusing a lot of time and energy on markets so far away from our culture such as China an India? Wouldnt it be better to focus more on current deals in Denmark and Scandinavia such as Matas to make sure the danish market becomes well established and recognised by danish retail customers before expanding to a market like India? It seems risky to focus so much on new markets, when nearby markets is not established yet?
You wrote in the report that the first product should have been approved by the chinese FDA today, if it hasnt been, isnt that a pretty dumb thing to pinpoint a date if you arent sure, especially when all your other timelines projections has gone out the window? All from the turnover projections from the start 150mDDK to 1mDDK to the dates of the timeline regarding the joint venture with rong shi? Isnt it something that you think your investors begins to get tired of all the "missed" projections et.c.. Wouldnt it be reasonable to have a bit more conservative take on things escpecially when talking to investors so we doesnt get dissappointed every time, and just dropping in trust from us?
What happens with the company if there are not enough approvals from the Chinese fda to get the first 30M DKK from rongshi? Do you have a plan B or will that be the end?
Has Rong Shi visited Copenhagen during the month of July?
According to the previous presentation, "JV" was to be signed during the month of July. What happened?
You expected a first approval from the Chinese FDA yesterday. Status?
You have barely been able to deliver on your communication in the past and now you have stated that you expect approval from China on 7/8, how do you think the market will react and what credibility does the management show when target after target turns out to be overly optimistic?
Your sales target for 2023 was heavily revised down to 1 million, how will you be able to sell for 62 million within a year after the first payment from RongShi, 62 million is a sum you have never been close to in terms of sales?
How is the short-term financing going?
Why hasn't Kapital Partner been able to provide you with it?
How do you think your investors that invested in the TO(around 9dkk/share) feel with the pumped up expectations last year, and then you go and cut the projections of the sales with over 90%, and now you cant blame everything on macro-economics since not even the flight-business dropped that much in turnover during the covid-pandemic.